Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Form 8-K

sec.gov

8-K — Rafael Holdings, Inc.

Accession: 0001213900-26-113564

Filed: 2026-10-29

Period: 2026-10-29

CIK: 0001713863

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — ea0309961-8k_rafael.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED OCTOBER 29, 2026, REPORTING THE RESULTS OF OPERATIONS FOR THE FISCAL QUARTER AND FISCAL YEAR ENDED JULY 31, 2026 (ea030996101ex99-1.htm)

EX-99.2 — PRESS RELEASE, DATED OCTOBER 29, 2026 (ea030996101ex99-2.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0309961-8k_rafael.htm · Sequence: 1

false

0001713863

0001713863

2026-10-29

2026-10-29

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): October 29, 2026

RAFAEL

HOLDINGS, INC.

(Exact

name of registrant as specified in its charter)

Delaware

1-38411

82-2296593

(State or other jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

520 Broad Street

Newark, New Jersey

07102

(Address of principal executive offices)

(Zip Code)

Registrant’s

telephone number, including area code: 212 658-1450

Not

Applicable

(Former

name or former address, if changed since last report.)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the

Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the

Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b)

under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c)

under the Exchange Act (17 CFR 240.13e-4(c))

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

If

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities

registered pursuant to Section 12(b)-2 of the Exchange Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Class B common stock, par value $0.01 per share

RFL

New York Stock Exchange

Item 2.02. Results of Operations and Financial

Condition.

On October 29, 2026, Rafael Holdings, Inc. (the “Company”)

distributed over a wire service and posted an earnings release to the investors page of its website (www.rafaelholdings.com) announcing

its results of operations for the fiscal quarter and fiscal year ended July 31, 2026. A copy of the earnings release concerning the foregoing

results is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The Company is furnishing the information contained

in this Report, including Exhibit 99.1, pursuant to Item 2.02 of Form 8-K promulgated by the Securities and Exchange Commission (the “SEC”).

This information shall not be deemed to be “filed” with the SEC or incorporated by reference into any other filing with the

SEC unless otherwise expressly stated in such filing. In addition, this Report and the press release contain statements intended as “forward-looking

statements” that are subject to the cautionary statements about forward-looking statements set forth in the press release.

Item

7.01. Regulation FD

On October 29, 2026, the Company distributed over a wire service and

posted the attached press release (the “Release”) to the investors page of its website announcing Cyclo Therapeutics, LLC,

has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of remibetadex (Trappsol®

Cyclo™, previously identified as intravenous hydroxypropyl-β-cyclodextrin), for the proposed indication of the treatment of

the neurovisceral manifestations of Niemann-Pick Disease Type C (NPC) in adult and pediatric patients from birth. NPC is a rare, fatal

and progressive genetic disorder for which there is no known cure. The Company also announced that the United States Adopted Names (USAN)

Council has assigned the nonproprietary name “remibetadex” to the compound known until now as intravenous hydroxypropyl-β-cyclodextrin.

A copy of the Release is furnished herewith as Exhibit 99.2 and is

incorporated herein by reference.

The Company is furnishing the information contained in this Report,

including Exhibit 99.2, pursuant to Item 7.01 of Form 8-K

promulgated by the Securities and Exchange Commission (the “SEC”).

This information shall not be deemed to be “filed” with the SEC or incorporated by reference into any other filing with the

SEC unless otherwise expressly stated in such filing. In addition, this Report and the press release contain statements intended as “forward-looking

statements” that are subject to the cautionary statements about forward-looking statements set forth in the press release.

Item 8.01. Other Events.

The information contained in Item 7.01 above is incorporated herein

by reference into this Item 8.01.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit No.

Document

99.1

Press Release, dated October 29, 2026, reporting the results of operations for the fiscal quarter and fiscal year ended July 31, 2026.

99.2

Press Release, dated October 29, 2026.

104

Cover Page Interactive Data File, formatted in Inline XBRL document.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act

of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RAFAEL HOLDINGS, INC.

By:

/s/

David Polinsky

Name:

David Polinsky

Title:

Chief Financial Officer

Dated: October 29, 2026

2

EXHIBIT INDEX

Exhibit

Number

Document

99.1

Press Release, dated October 29, 2026, reporting the results of operations for the fiscal quarter and fiscal year ended July 31, 2026.

99.2

Press Release, dated October 29, 2026.

104

Cover Page Interactive Data File, formatted in Inline XBRL document.

3

EX-99.1 — PRESS RELEASE, DATED OCTOBER 29, 2026, REPORTING THE RESULTS OF OPERATIONS FOR THE FISCAL QUARTER AND FISCAL YEAR ENDED JULY 31, 2026

EX-99.1

Filename: ea030996101ex99-1.htm · Sequence: 2

Exhibit 99.1

Rafael Holdings Reports Fourth Quarter and Full

Year Fiscal 2026

Financial Results and Provides Corporate Update

NEWARK,

NJ – October 29, 2026 (GLOBE NEWSWIRE) - Rafael Holdings,

Inc. (NYSE: RFL) today reported its financial results for the fourth quarter and full fiscal year 2026 ended July 31, 2026.

Fiscal 2026 and Recent Corporate Highlights

● NDA submitted for remibetadex (Trappsol® Cyclo™). On October 28, 2026, Cyclo Therapeutics submitted a New Drug Application

(NDA) to the FDA seeking approval of remibetadex for the treatment of Niemann-Pick Disease Type C. The NDA is supported by the Phase 3

TransportNPC™ study, completed in June 2026, which did not meet its primary endpoint in the overall population (p=0.19) but showed

71% slowing of disease progression in a prespecified analysis of patients receiving background miglustat and/or leucine therapy (p=0.046),

and by an overall survival analysis versus matched registry controls. The NDA includes a request for a rare pediatric disease priority

review voucher.

● MIT license in Alzheimer’s disease. In April 2026, Cyclo entered into an exclusive, worldwide license with the Massachusetts

Institute of Technology for the use of hydroxypropyl-β-cyclodextrin in Alzheimer’s disease.

● LipoMedix. In June 2026, an investigator-initiated Phase II trial of Promitil® with radiotherapy in patients with cisplatin-ineligible

head and neck cancer was launched in Israel.

● Rafael Medical Devices. Continued the U.S. commercial build-out of the FDA-cleared VECTR™ System, including its regional

distributor network.

Rafael Holdings, Inc. Fourth Quarter Fiscal Year 2026 Financial

Results

As of July 31, 2026, we had cash and cash equivalents of $22.1 million.

For the three months ended July 31, 2026, we recorded a net loss attributable

to Rafael Holdings of $9.2 million, or $0.18 per share, versus a net loss of $12.1 million, or $0.28 per share in the year ago period.

The year over year decrease in net loss is largely attributable to a decrease in general and administrative expenses.

Research and development expenses were $7.5 million for each of the

three months ended July 31, 2026 and 2025.

General and administrative expenses were $2.4 million for the three

months ended July 31, 2026, compared to $5.5 million in the year ago period. The year over year decrease relates to a decrease in payroll,

stock-based compensation expense and professional fees.

Rafael Holdings, Inc. Full Fiscal Year 2026 Financial Results

For the twelve months ended July 31, 2026, we recorded a net loss attributable

to Rafael Holdings of $29.6 million, or $0.58 per share, versus a net loss of $30.5 million, or $1.04 per share in the year ago period.

The year over year decrease in net loss reflects a $4.4 million gain on Cornerstone’s settlements of accounts payable and convertible

notes payable and the absence of prior-year unrealized losses on our investment in Cyclo, partially offset by higher research and development

expenses following the consolidation of Cyclo Therapeutics in March 2025.

Research and development expenses were $24.3 million for the twelve

months ended July 31, 2026, compared to $12.8 million in the year ago period. The year over year increase was primarily attributable to

a $13.4 million increase in Cyclo’s research and development expenses in fiscal 2026, as well as an increase in R&D stock-based

compensation expense of $0.4 million, offset by decreases in R&D payroll of $1.5 million, and in clinical trial and other expenses

of $0.8 million.

General and administrative expenses were $9.7 million for the twelve

months ended July 31, 2026, compared to $13.8 million in the year ago period. The decrease of $4.1 million versus the prior year is primarily

attributable to decreases in professional fees of $1.3 million, primarily due to merger-related costs in the prior year, stock-based compensation

expense of $1.2 million, payroll expense of $0.6 million due to terminations, and other expenses.

About Rafael Holdings, Inc.

Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals

and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. Our lead candidate is remibetadex

(Trappsol® Cyclo™), for which we have completed a pivotal Phase 3 study in Niemann-Pick Disease Type C (“NPC”) and

submitted an NDA to the FDA in October 2026. NPC is a rare, fatal and progressive genetic disorder. We also hold interests in other clinical-stage

and early-stage pharmaceutical development companies and an orthopedic-focused medical device company.

Forward Looking Statements

This press release contains forward-looking statements within the meaning

of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters

of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations

surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; the FDA’s review of

our NDA for remibetadex, including whether it will be accepted for filing, granted priority review or approved; our eligibility for and

ability to monetize a priority review voucher; plans regarding the further evaluation of clinical data; and the potential of our pipeline.

These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that

may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements

expressed or implied by the forward-looking statements, including, but not limited to, the risk that the FDA may not accept for filing

or approve our NDA, including because the Phase 3 TransportNPC™ study did not meet its primary endpoint in the overall population,

our need for additional financing and the substantial doubt about our ability to continue as a going concern, and those disclosed under

the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended July 31, 2026, and our other filings with

the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in

this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While

we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent

events cause our views to change.

Contact:

Barbara Ryan

barbara.ryan@rafaelholdings.com

(203) 274-2825

# # #

2

RAFAEL HOLDINGS, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per

share data)

July 31,

2026

2025

ASSETS

CURRENT ASSETS

Cash and cash equivalents

$ 22,074

$ 52,769

Prepaid clinical costs

1,839

1,045

Other receivables

—

1,206

Accounts receivable, net of allowance for credit losses of $245 at July 31, 2026 and July 31, 2025

444

627

Inventory

377

281

Prepaid expenses and other current assets

1,083

786

Total current assets

25,817

56,714

Property and equipment, net

1,503

1,596

Non-current prepaid clinical costs

457

1,399

Convertible notes receivable classified as available-for-sale

2,044

1,858

Goodwill

19,939

19,939

Intangible assets, net

863

994

In-process research and development

31,575

31,575

Investments

750

—

Other assets

107

34

TOTAL ASSETS

$ 83,055

$ 114,109

LIABILITIES AND EQUITY

CURRENT LIABILITIES

Accounts payable

$ 7,014

$ 6,893

Accrued expenses

2,943

3,304

Convertible notes payable

608

614

Due to related parties, net

355

723

Other current liabilities

67

66

Total current liabilities

10,987

11,600

Accrued expenses, noncurrent

—

3,895

Convertible notes payable, noncurrent

2

78

Deferred income tax liability

43

138

Other liabilities

53

27

TOTAL LIABILITIES

$ 11,085

$ 15,738

COMMITMENTS AND CONTINGENCIES

EQUITY

Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of July 31, 2026 and July 31, 2025

8

8

Class B common stock, $0.01 par value; 200,000,000 shares authorized, 51,393,279 issued and outstanding (excluding treasury shares of 101,487) as of July 31, 2026, and 50,789,697 issued and outstanding (excluding treasury shares of 101,487) as of July 31, 2025

514

508

Additional paid-in capital

323,438

322,161

Accumulated deficit

(261,898 )

(232,263 )

Treasury stock, at cost; 101,487 Class B shares as of July 31,  2026 and July 31,  2025

(168 )

(168 )

Accumulated other comprehensive income related to unrealized income on available-for-sale securities

544

358

Accumulated other comprehensive income related to foreign currency translation adjustment

3,871

3,787

Total equity attributable to Rafael Holdings, Inc.

66,309

94,391

Noncontrolling interests

5,661

3,980

TOTAL EQUITY

71,970

98,371

TOTAL LIABILITIES AND EQUITY

$ 83,055

$ 114,109

3

RAFAEL HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per

share data)

Three Months Ended

July 31,

Year Ended

July 31,

2026

2025

2026

2025

(unaudited)

Revenues

$ 244

$ 350

$ 874

$ 917

Cost of infusion technology revenue

—

—

—

106

Cost of product revenue

13

19

42

28

G&A expenses

2,444

5,497

9,704

13,781

R&D expenses

7,467

7,547

24,333

12,823

Depreciation and amortization

51

50

204

288

Loss on impairment of goodwill

—

—

—

3,050

Operating Loss

(9,731 )

(12,763 )

(33,409 )

(29,159 )

Interest income

213

467

1,236

1,996

Realized gain on available-for-sale securities

—

—

—

178

Unrealized (loss) gain on investment - Cyclo

—

—

—

(5,144 )

Unrealized (loss) gain on convertible notes receivable, due from Cyclo

—

—

—

(719 )

Interest expense

(6 )

(168 )

(333 )

(658 )

Gain on settlement of accounts payable and convertible notes payable

464

—

4,422

—

Other income

63

236

117

310

Loss before income taxes

(8,997 )

(12,228 )

(27,967 )

(33,196 )

Benefit from taxes

65

174

13

2,553

Consolidated net loss

(8,932 )

(12,054 )

(27,954 )

(30,643 )

Consolidated net loss

(8,932 )

(12,054 )

(27,954 )

(30,643 )

Net income (loss) attributable to noncontrolling interests

244

40

1,681

(123 )

Net loss attributable to Rafael Holdings, Inc.

$ (9,176 )

$ (12,094 )

$ (29,635 )

$ (30,520 )

Loss per share attributable to common stockholders

Basic and Diluted

$ (0.18 )

$ (0.28 )

$ (0.58 )

$ (1.04 )

Weighted average number of shares used in calculation of loss per share - basic and diluted

51,586,276

43,011,360

51,393,118

29,422,221

4

EX-99.2 — PRESS RELEASE, DATED OCTOBER 29, 2026

EX-99.2

Filename: ea030996101ex99-2.htm · Sequence: 3

Exhibit

99.2

Rafael

Holdings Announces Submission of New Drug Application to FDA for Trappsol®

Cyclo™ (remibetadex) for the

Treatment of Niemann-Pick Disease Type C

NDA

supported by the Phase 3 TransportNPC™ study, data from earlier clinical studies, and

an overall survival analysis versus

external registry controls

Remibetadex

has received Orphan Drug, Fast Track and Rare Pediatric Disease

designations from the FDA; approval would make remibetadex eligible for

a Rare Pediatric

Disease Priority Review Voucher

United

States Adopted Names (USAN) Council assigns nonproprietary name “remibetadex” to Trappsol® Cyclo™

NEWARK,

N.J., October 29, 2026 — Rafael Holdings, Inc. (NYSE: RFL) today announced that its subsidiary, Cyclo Therapeutics, LLC, has

submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of remibetadex (Trappsol®

Cyclo™, previously identified as intravenous hydroxypropyl-β-cyclodextrin), for the proposed indication of the

treatment of the neurovisceral manifestations of Niemann-Pick Disease Type C (NPC) in adult and pediatric patients from birth. NPC is

a rare, fatal and progressive genetic disorder for which there is no known cure. The Company also announced that the United States Adopted

Names (USAN) Council has assigned the nonproprietary name “remibetadex” to the compound known until now as intravenous hydroxypropyl-β-cyclodextrin.

Within

60 days of receiving the application, the FDA will determine whether the application is filed and, if filed, whether Priority Review

will be granted. If the application is filed, the FDA will assign a Prescription Drug User Fee Act (PDUFA) target action date.

“This

submission is an important milestone for Rafael Holdings and, most importantly, for patients living with NPC,” said Howard Jonas,

Chairman and Chief Executive Officer of Rafael Holdings. “I believe the totality of the data, including the Phase 3 trial results

and the overall survival analysis, supports the potential of remibetadex for patients with limited treatment options. Pending FDA approval,

we are excited to bring remibetadex to patients and families who urgently need new options to treat NPC.”

The NDA includes results from the global, double-blind, placebo-controlled

Phase 3 TransportNPC™ study. Although the study did not achieve statistical significance on its primary endpoint, remibetadex

showed a directionally favorable 64% relative slowing of disease progression compared with placebo (p=0.19) and in a prespecified analysis

of patients receiving background therapy (approximately 83% of the study population), remibetadex showed a 71% relative slowing of disease

progression (p=0.046). The NDA also includes data from earlier clinical studies and an overall survival analysis in which remibetadex

was associated with an 85% reduction in the risk of mortality in patients with infantile-onset NPC compared with matched registry controls

(p=0.044). Remibetadex was generally well tolerated, with no new safety signals observed, although serious adverse events occurred more

frequently with remibetadex than with placebo (35.9% vs. 16.7%). Topline results from TransportNPC™ were reported on

September 30, 2026.

“The

remibetadex NDA is the culmination of more than 15 years of research and investment and, if approved, could help address a significant

unmet need in a rare, and fatal disease,” said Joshua Fine, Chief Operating Officer of Rafael Holdings. “With the data in

the NDA and Orphan Drug, Fast Track and Rare Pediatric Disease designations in place, upon the FDA’s filing of the NDA, we believe

remibetadex is well positioned for review, and an approval would make it eligible for a Priority Review Voucher, a potential source of

non-dilutive capital. With this important milestone completed, we are preparing for a potential commercial launch, and we look forward

to working with the FDA as the regulatory review process advances. We are grateful to the investigators, patients, families and advocates

who made this milestone possible.”

About

Remibetadex (Trappsol® Cyclo™)

Remibetadex

is an investigational, intravenously administered therapy containing a proprietary formulation of hydroxypropyl-β-cyclodextrin and

is being developed for the treatment of the neurovisceral manifestations of Niemann-Pick Disease Type C (NPC) in adult and pediatric

patients from birth. Remibetadex is designed to mobilize cholesterol from late endosomes and lysosomes, facilitating the transport of

accumulated cholesterol out of cells so it can be further processed and excreted. Remibetadex has been granted Orphan Drug, Fast Track

and Rare Pediatric Disease designations by the FDA for the treatment of NPC.

Remibetadex

is an investigational product and has not been approved by the FDA or any other regulatory agency for any indication.

About

Rafael Holdings, Inc.

Rafael

Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that

develop pharmaceuticals and medical devices. Our lead candidate is remibetadex (Trappsol® Cyclo™, previously

identified as intravenous hydroxypropyl-β-cyclodextrin) for which we have completed a pivotal Phase 3 study in Niemann-Pick Disease

Type C (“NPC”) and submitted an NDA to the FDA in October 2026. NPC is a rare, fatal and progressive genetic disorder. We

also hold interests in other clinical-stage and early-stage pharmaceutical development companies and an orthopedic-focused medical device

company.

Forward-Looking

Statements

This

press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements

contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including

without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress

of our product candidates; the FDA’s review of our NDA, including whether the NDA will be accepted for filing or receive Priority

Review; our eligibility for a Priority Review Voucher; our commercial preparations; plans regarding the further evaluation of clinical

data; and the potential of our pipeline. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties

and other important factors that may cause our actual results, performance or achievements to be materially different from any future

results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the risk

that the FDA may not accept for filing or approve an NDA for remibetadex based on the available data; the risk that we may not receive

or be able to monetize a Priority Review Voucher; and those disclosed under the caption “Risk Factors” in our Annual Report

on Form 10-K for the year ended July 31, 2026, and our other filings with the SEC. These factors could cause actual results to differ

materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent

management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some

point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Contact:

Barbara

Ryan

Barbara.ryan@rafaelholdings.com

(203)

274-2825

#

# #

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Oct. 29, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 29, 2026

Entity File Number

1-38411

Entity Registrant Name

RAFAEL

HOLDINGS, INC.

Entity Central Index Key

0001713863

Entity Tax Identification Number

82-2296593

Entity Incorporation, State or Country Code

DE

Entity Address, Address Line One

520 Broad Street

Entity Address, City or Town

Newark

Entity Address, State or Province

NJ

Entity Address, Postal Zip Code

07102

City Area Code

212

Local Phone Number

658-1450

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Class B common stock, par value $0.01 per share

Trading Symbol

RFL

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

X

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

na

Period Type:

duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration